Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan.

ABSTRACT:

Purpose

The real-world effectiveness and safety of abiraterone or enzalutamide in the Asian population with metastatic castration-resistant prostate cancer (mCRPC) remains unclear.

Methods

Using the Taiwan National Health Insurance Research Database, we identified a cohort of 3056 patients diagnosed with mCRPC receiving abiraterone or enzalutamide from January 1, 2017 through April 30, 2020, followed until December 31, 2021. We applied inverse probability of treatment weighting (IPTW) to balance the treatment groups and compare outcomes between the two treatment groups. Effectiveness outcomes included all-cause death, prostate cancer-related death, and treatment failure. Safety outcomes included major adverse CV events (MACE), fractures, and venous thromboembolism (VTE).

SUBMITTER: Huang WK 

PROVIDER: S-EPMC12504157 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature